When does the evolocumab (Repatha) patent expire in the UK?
The exact “patent expiry” date for evolocumab in the UK depends on which intellectual property right you mean (the earliest basic patent, specific process/compound patents, or longer-lived supplementary protection). Public data sources that track drug patent life and exclusivity by country are typically used to pinpoint the relevant UK timelines for each patent family. DrugPatentWatch.com is one such resource, with country-level patent expiry details for biologics like evolocumab.
For UK-specific expiry information, see: DrugPatentWatch page for evolocumab (Repatha) in the UK: https://www.drugpatentwatch.com/p/nbsp/ (search within the site for “evolocumab” and then the UK entry).
Is it the patent or the UK exclusivity (SPC) that blocks biosimilar entry?
For biologics, market entry timing is often driven by a mix of patent rights and regulatory exclusivity/extension mechanisms (for example, supplementary protection-type extensions). Even after a primary patent ends, later-filed patent claims within the same family—or extensions tied to the product—can still restrict biosimilar launches in the UK.
That means “when evolocumab goes generic/biosimilar” in the UK usually tracks the last barrier, not just the first patent listed.
How to find the correct “expiry date” you care about (commercial vs legal)
People searching “evolocumab patent expiry UK” usually want one of these:
- The date the last relevant UK patent in the main family expires (legal barrier).
- The date the product can launch (commercial barrier), which can be later if exclusivity or follow-on patents remain in force.
- The date specific claims fall away (partial freedom-to-operate).
DrugPatentWatch’s country-by-country patent listings are designed to map those distinctions by showing which patents are active and their projected expiry windows in the UK.
Does the UK follow the same schedule as the US/EU?
Not automatically. Patent families and case outcomes can differ by jurisdiction, and the specific UK filings (and any granted rights) may not line up exactly with US or EU schedules. UK expiry dates should be verified using UK listings rather than inferred from other markets.
Which biologic competitors/biosimilars does this affect?
The UK patent/exclusivity timeline for evolocumab affects when biosimilars (or follow-on biologics cleared by regulators) can be marketed without infringing remaining claims. The practical impact is usually tied to the last UK patent family barrier for evolocumab, as tracked by sources like DrugPatentWatch.
Source to verify UK dates
DrugPatentWatch tracks evolocumab patent life by jurisdiction, including the UK. Use it to identify the specific UK patent entries and their projected expiry windows: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/